Beyond Technology: Exploring, Defining, and Breaking Down the Barriers in Decentralized Trials
Associated with
Katherine Vandebelt Katherine Vandebelt
Beyond Technology: Exploring, Defining, and Breaking Down the Barriers in Decentralized Trials

In our continued effort to understand the journey organizations must take to move towards decentralized and hybrid trials, we developed a series of webcasts tackling the topics and questions surrounding "Why" and "How" to make the change to these new world approaches in clinical trials.
Oracle Health Sciences, with support from The Avoca Group, is contacting pharmaceutical professionals such as yourself about how organizations are approaching the adoption of decentralized clinical trials, and the potential impact on sponsors and vendors conducting the clinical research. After completion of the confidential survey you may request an executive summary of the key findings from this research.

More Ways to Read:
🧃 Summarize The key takeaways that can be read in under a minute
Sign up to unlock